| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Almost all thiophanate-methyl is excreted from the body within 24 hours; the portion remaining in tissues after 24 hours is also primarily excreted within 96 hours. Thiophanate-methyl is rapidly absorbed and excreted. At high dose levels or after sustained low-dose exposure, the absorption process clearly exhibits some saturation, and the elimination half-life is prolonged. In all cases, blood concentrations decrease rapidly, and tissue concentrations are very low by day 4 post-exposure. Metabolism/Metabolites Studies in mice using four radiolabeled thiophanate-methyl compounds (C on the ring, thiourea carbon on the methyl carbon, and S on the methyl carbon) showed that the C=S bond is largely broken before absorption by the gastrointestinal tract. A portion of the methyl carbon is apparently metabolized to carbon dioxide. The major urinary metabolites are carbendazim and its 6-hydroxy derivatives; these are excreted as O- or N-glucuronides. Compounds in which the two =S substituted by =O on the thiophanate-methyl methyl group are minor metabolites. Some other metabolites detectable by radiometric thin-layer chromatography have not yet been identified. The main metabolic changes include hydrolysis of the terminal side chain, closure of the remaining side chain, and oxidation of the phenyl moiety to produce methylhydroxybenzimidazole carbamate. The main urinary metabolites are bound to sulfate. Fecal residues mainly consist of thiophanate-methyl and benzene ring hydroxylated products. |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 1,700 mg/m³/4h Non-human Toxicity Values Oral LD50 in rats: 6640 mg/kg Intraperitoneal LD50 in rats: 1140 mg/kg Oral LD50 in mice: 3400 mg/kg Intraperitoneal LD50 in mice: 790 mg/kg For more complete non-human toxicity data on thiophanate-methyl (21 types), please visit the HSDB record page. |
| Additional Infomation |
According to the U.S. Environmental Protection Agency (EPA), thiophanate-methyl can cause reproductive toxicity in both females and males. Thiophanate-methyl is a colorless crystal or light brown powder. (NTP, 1992) Thiophanate-methyl belongs to the thiourea class of compounds and is a dimethyl ester of (1,2-phenylenediamine)dicarbamate. It is a fungicide effectively controlling a variety of diseases in fruits, vegetables, lawns, and other crops, including eye spot, scab, powdery mildew, and gray mold. It is an antifungal pesticide. It belongs to the thiourea, carbamate, benzimidazole precursor fungicide, and carbamate fungicide classes. Its function is similar to 1,2-phenylenediamine. Thiophanate-methyl™ is a systemic fungicide. The U.S. Environmental Protection Agency first registered this compound for use as a fungicide in 1973. It is effective against a variety of fungal pathogens, including: eye spot and other diseases in cereal crops; scab in apples and pears; Monilla and collodion in apples; Monilla in stone fruits; fruit tree canker; and powdery mildew in pome fruits, stone fruits, vegetables, cucurbits, strawberries, grapevines, and roses. Thiophanate-methyl is also used on almonds, pecans, tea, coffee, peanuts, soybeans, tobacco, chestnuts, sugarcane, citrus fruits, figs, hops, mulberries, and many other crops. It is a nematicide used in livestock and also has fungicidal activity. Mechanism of Action: As a class of compounds, thiocarbamates do not produce a consistent pattern of cholinesterase inhibition. In subchronic toxicity studies in rats, compared with the control group, serum cholinesterase activity increased by 22-38% in male rats at doses ≥293.2 mg/kg/day, while it decreased by 25-28% in female rats. In a rat chronic toxicity/carcinogenicity study, male rats treated with 280.6 mg/kg/day (HDT) showed increased serum cholinesterase activity at 6 and 12 months (41-42%), but decreased at 24 months (-38%). Female rats treated with ≥63.5 mg/kg/day showed slightly decreased cholinesterase activity at 6 and 12 months (180-35%). To elucidate the mechanisms of thyroid tumorigenesis, we conducted a series of short-term studies to determine whether TM possesses antithyroid activity. These studies showed that treatment with TM at 6000 ppm (equivalent to the HDT dose in the rat chronic toxicity/carcinogenicity study) for 2 to 8 days resulted in hepatomegaly and thyroid enlargement, increased circulating TSH levels, and a decreased T3/T4 ratio. The activity of several hepatic microsomal enzymes, including UDP-glucuronyltransferase, was also increased. Changes in liver and thyroid weight were reversible, but the reversibility of changes in circulating hormone levels and microscopic effects has not been assessed. T4 supplementation in test animals prevented goiter and elevated TSH levels, but did not prevent liver enlargement. TM also appeared to have a slight inhibitory effect on microsomal thyroid peroxidase. These data are crucial for fully supporting this mechanism.
|
| Molecular Formula |
C12H14N4O4S2
|
|---|---|
| Molecular Weight |
342.3940
|
| Exact Mass |
342.045
|
| CAS # |
23564-05-8
|
| Related CAS # |
Thiophanate-methyl-d6;1398065-77-4
|
| PubChem CID |
3032791
|
| Appearance |
Colorless crystals
Colorless prisms Colorless crystalline solid |
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
478.4ºC at 760 mmHg
|
| Melting Point |
172°C
|
| Vapour Pressure |
2.58E-09mmHg at 25°C
|
| Index of Refraction |
1.709
|
| LogP |
1.16
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S=C(N([H])C(=O)OC([H])([H])[H])N([H])C1=C([H])C([H])=C([H])C([H])=C1N([H])C(N([H])C(=O)OC([H])([H])[H])=S
|
| InChi Key |
QGHREAKMXXNCOA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14N4O4S2/c1-19-11(17)15-9(21)13-7-5-3-4-6-8(7)14-10(22)16-12(18)20-2/h3-6H,1-2H3,(H2,13,15,17,21)(H2,14,16,18,22)
|
| Chemical Name |
methyl N-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~876.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9206 mL | 14.6032 mL | 29.2065 mL | |
| 5 mM | 0.5841 mL | 2.9206 mL | 5.8413 mL | |
| 10 mM | 0.2921 mL | 1.4603 mL | 2.9206 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.